Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Sirnaomics Ltd (2257)

Hong Kong
Currency in HKD
Disclaimer
6.30
+0.24(+3.96%)
Closed
2257 Scorecard
Fair Value
Unlock Value
Day's Range
5.956.50
52 wk Range
5.6459.00
Bid/Ask
6.30 / 6.31
Prev. Close
6.06
Open
6.06
Day's Range
5.95-6.5
52 wk Range
5.64-59
Volume
4,413,850
Average Volume (3m)
3,181,294
1-Year Change
-88.73%
Shares Outstanding
86,815,730
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
How do you feel today about 2257?
Vote to see community's results!
or

Sirnaomics Company Profile

Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops product candidates for indications with medical needs in the United Sates, the People’s Republic of China, and Hong Kong. Its lead product candidates include STP705 for the treatment cutaneous squamous cell carcinoma in situ; basal cell carcinoma; cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; keloid scarless healing, hypertrophic scarring, and fat remodeling. The company’s lead product candidates also comprise STP707 to treat cholangiocarcinoma, hepatocellular carcinoma, liver metastases, etc.; metastatic cutaneous squamous cell carcinoma; non-small cell lung cancer; liver fibrosis; and lung fibrosis. It also develops STP355 for the treatment of pan cancer; STP369 to treat head and neck/bladder cancer; STP779 for the treatment of liver/lung/pancreatic cancer; STP702 for the treatment of influenza; RIM730 COVID-19 vaccine; and STP122G to treat anticoagulation/thrombosis. In addition, the company is developing STP125G to treat hypertriglyceridemia; and STP144G for the treatment of complement-mediated diseases. Sirnaomics Ltd. was founded in 2007 and is headquartered in Germantown, Maryland.

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.